Synthetic human pancreatic GRF
A majority of the idiopathic GH deficient children are thought to have defects in the hypothalamus resulting in a lack of GRF synthesis or secretion (Kaplan 1975) . Such a hypothesis could not be tested until recently, when Guillemin et al. (1982) reported the isolation and characterization of a GHreleasing peptide from a pancreatic tumor in a patient with acromegaly. This peptide contains 44 amino acids with an amidated carboxyl-terminus and is designated hpGRF-
44.
Synthetic replicates of hpGRF were found to be highly potent and specific for the release of GH in vitro (Brazeau et al., 1982a (Brazeau et al., , 1982b and in vivo (Wehrenberg et al., 1982a (Wehrenberg et al., , 1982b . The similarity between hpGRF and human hypothalamic GRF is corroborated by the many reports stating that hpGRFs are active in man (Thorner et al., 1983 ; Rosenthal et al., 1983 ; Takano et al., 1984) . With the availability of synthetic material, we undertook a study of the effects of hpGRF-44 on the release of GH in normal children of short stature and Human subjects One hundred and thirty nine normal children of short stature and 63 patients with GH deficiency were studied. Normal but short children had come to our hospital because of their short stature. Their height was below 2 SD of the mean height of Japanese boys and girls of the same age group in 86 subjects and between -2 SD and the mean height in 53 subjects.
Bone age, GH, T4, T3 and other pituitary hormones were measured. Normal but short children were defined as children with no physical abnormalities except short stature and no abnormal findings in the above mentioned hormone tested. A total of 100 males and 39 females, aged 4-18 years, were in this group.
The patients with GH deficiency consisted of 49 males and 14 females, aged 5-42 years. The diagnosis of GH deficiency was established on the basis of the failure of plasma GH to respond to insulin-induced hypoglycemia, glucagon-propranolol, and/or L-dopa. The GH deficiency in these patients was considered to be idiopathic in 47 patients (IGD) and to be secondary in 16 patients (SGD) (craniopharyngioma in 9, pinealoma in 2, meningitis in 2, others in 3). Ten patients had never been treated with human (h)GH, and five patients had ceased hGH treatment. The rest of the patients were treated with hGH for between 6 months and 7 years. hpGRF-44 administration was performed 2-4 days after the last hGH injection in these latter patients. All were receiving appropriate replacement therapy for other pituitary hormone deficiencies and had no detectable hGH antibody in their plasma.
Informed consent was obtained from each subject and/or the parents, and the experimental protocol was approved by the Human Subjects Investigation Committee of our department.
Peptide preparation
Human pancreatic growth hormone releasing factor (hpGRF-44) was synthesized as described (Guillemin et al., 1982) . One hundred mg of the peptide dissolved in 100 ml distilled water The insulin-induced hypoglycemic test (IT) was performed using iv 0.05-0.1 U/kg BW doses of regular insulin. Plasma GH and blood glucose were determined 0, 30, 60 and 90 min after the administration of insulin. The test was considered effective if the blood glucose values declined to less than 50 mg/dl or by 50 % or more. In the glucagon-propranolol (G-P) test, glucagon (2 mg, im) and propranolol (10 mg, po) were simultaneously administered, and blood was collected immediately before and 90, 120, 150 and 180 min after drug administration. In the L-dopa (250 mg, po) test, blood was withdrawn before and 30, 60, 90 and 120 min after the ingestion.
Plasma GH was measured with a commercial RIA kit (Eiken Chemical Co., Ltd., Tokyo, Japan). Human growth hormone from Kabi (Stockholm, Sweden) was used for labelling and as standard. The intra-and inter-assay coefficients of variation were 6.6 % and 8.0 % respectively. The minimal detectable plasma GH level was 1.0 ng/ml.
Bone age was estimated according to the standards of Greulich and Pyle (1959 respond with plasma GH above 5 ng/ml. Intravenous bolus administration of hp-GRF-44 produced facial flushing in two normal short children and one pituitary dwarf. The flushing appeared 1-2 min after the injection and disappeared within 3 min. However, there was no accompanying change in the plus rate. All other blood analyses, including blood count, serum electrolytes, and serum chemistries, were normal. stature, but there were no patients with GH deficiency whose plasma GH rose above 20 ng/ml. These data suggest that half of the patients with GH deficiency have little GH reserve in the pituitary.
